Needham Reiterates Buy on Cartesian Therapeutics, Maintains $40 Price Target

Benzinga · 1d ago
Needham analyst Gil Blum reiterates Cartesian Therapeutics (NASDAQ:RNAC) with a Buy and maintains $40 price target.